From Sept 22 Ann
These revised clinical plans have substantially reduced the Company's budgeted trial costs, and with the expected additional R&D tax incentive rebates, the Company now estimates that it can fund both the Company and the trial into 4Q’23.
Ann: Chief Executive Officer and Managing Director Appointment, page-36
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 13.0¢ | $378.0K | 2.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 516956 | 4 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |